Beactica
1 known investors
Beactica Therapeutic uses targeted protein degradation (TPD) technology, including its Eclipsor™ platform, to develop precision therapeutics for disease targets previously considered undruggable. The company focuses on advancing novel therapeutic candidates toward clinical development.
Founders & leadership
PK
Per KällbladChief Executive Officer
Investors · 1
Competitors · 4
by search overlapBioworld16 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Drughunter9 shared keywordsDrug Hunter publishes educational content, molecule case studies, patent highlights, and analysis on small molecule and biologic drug discovery for medicinal chemists and pharmaceutical R&D professionals. The site covers therapeutic targets, clinical-stage molecules, and drug development strategies across oncology, neurology, and other disease areas.
Verastem7 shared keywordsVerastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients. The company focuses on oncology therapeutics including small molecules and monoclonal antibodies targeting pathways such as RAS, KRAS, and immune modulation.
Labcorp7 shared keywordsLabcorp provides clinical laboratory testing, diagnostics, and lab data services for patients, healthcare providers, and biopharma companies, including genetic health panels, oncology testing, and self-ordered lab tests. It also offers AI-powered tools such as a results-explaining consumer app, a diagnostic assistant integrated into EHRs, and a laboratory data analytics platform to support drug development and clinical research.
Companies competing with Beactica for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Beactica do?
- Beactica Therapeutic uses targeted protein degradation (TPD) technology, including its Eclipsor™ platform, to develop precision therapeutics for disease targets previously considered undruggable. The company focuses on advancing novel therapeutic candidates toward clinical development.
- Who are Beactica's investors?
- Beactica's investors include Almi Invest.